IDEXX Laboratories, Inc.

NasdaqGS:IDXX Stock Report

Market Cap: US$41.3b

IDEXX Laboratories Future Growth

Future criteria checks 3/6

IDEXX Laboratories is forecast to grow earnings and revenue by 9.9% and 8.7% per annum respectively. EPS is expected to grow by 11.1% per annum. Return on equity is forecast to be 35.3% in 3 years.

Key information

9.9%

Earnings growth rate

11.1%

EPS growth rate

Medical Equipment earnings growth16.9%
Revenue growth rate8.7%
Future return on equity35.3%
Analyst coverage

Good

Last updated16 Jul 2024

Recent future growth updates

IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 03
IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital

Jul 02
A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital

Looking For Fast Growth In Healthcare? IDEXX Has You Covered

Jun 28

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Jun 04
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?

May 21
Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?

IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 03
IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You

Apr 27
What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You

IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet

Apr 11
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet

IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)

Apr 08

Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jan 30
Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified

Jan 16

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

Jan 15
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit

Dec 31
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit

IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly

Dec 15
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly

Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Oct 26
Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching

Oct 10
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching

Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

Sep 07
Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jul 04
Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

May 31
These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?

Apr 05
At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?

Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly

Feb 22
Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly

Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Jan 05
Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

Nov 24
Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?

When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Sep 20
When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Outstanding Business, But Valuation Is Key

Aug 15

These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

Aug 15
These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well

IDEXX Laboratories Stock Is Very Expensive

Aug 08

IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M

Aug 02

Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?

Jul 26
Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?

Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today

Jul 12
Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today

Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Jun 16
Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories: Great Business, But Still Overvalued

May 25

We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease

May 06
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease

Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?

Apr 23
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?

With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting

Apr 09
With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting

Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Mar 07
Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

IDEXX Laboratories And Its Real Value

Feb 02

Earnings and Revenue Growth Forecasts

NasdaqGS:IDXX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,7601,1651,0701,2239
12/31/20254,3261,0359841,10411
12/31/20243,9409218841,08711
3/31/20243,725867797921N/A
12/31/20233,661845773907N/A
9/30/20233,588823680830N/A
6/30/20233,514791593747N/A
3/31/20233,431699456612N/A
12/31/20223,367679384543N/A
9/30/20223,340670438580N/A
6/30/20223,309664429578N/A
3/31/20223,274735605746N/A
12/31/20213,215745636756N/A
9/30/20213,135757663765N/A
6/30/20213,047728694770N/A
3/31/20212,858674666745N/A
12/31/20202,707582540648N/A
9/30/20202,591497445585N/A
6/30/20202,475460366524N/A
3/31/20202,457437286453N/A
12/31/20192,407428304459N/A
9/30/20192,351423290439N/A
6/30/20192,291407274418N/A
3/31/20192,252390262400N/A
12/31/20182,213377277400N/A
9/30/20182,170330280386N/A
6/30/20182,117307296386N/A
3/31/20182,045284300377N/A
12/31/20171,969263N/A373N/A
9/30/20171,906277N/A353N/A
6/30/20171,862263N/A343N/A
3/31/20171,820245N/A343N/A
12/31/20161,775222N/A339N/A
9/30/20161,732214N/A312N/A
6/30/20161,690202N/A289N/A
3/31/20161,637192N/A258N/A
12/31/20151,602192N/A222N/A
9/30/20151,554174N/A170N/A
6/30/20151,531182N/A186N/A
3/31/20151,508182N/A188N/A
12/31/20141,486182N/A236N/A
9/30/20141,488199N/A274N/A
6/30/20141,443193N/A259N/A
3/31/20141,405190N/A258N/A
12/31/20131,377188N/A246N/A
9/30/20131,343188N/A250N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDXX's forecast earnings growth (9.9% per year) is above the savings rate (2.4%).

Earnings vs Market: IDXX's earnings (9.9% per year) are forecast to grow slower than the US market (14.8% per year).

High Growth Earnings: IDXX's earnings are forecast to grow, but not significantly.

Revenue vs Market: IDXX's revenue (8.7% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: IDXX's revenue (8.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDXX's Return on Equity is forecast to be high in 3 years time (35.3%)


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.